Nina Capital describes itself on its homepage as "a specialized venture capital firm investing exclusively at the intersection of healthcare and technology", investing in "healthcare transformation powered by information technology led by need-driven founders". Its stated scope is health technology built on data, computing and networks, and it states plainly what it does not do: "( what we don't do: drugs and vaccines )". The firm invests at pre-seed and seed, with follow-on reserved for portfolio companies reaching Series A readiness, at "ticket sizes from 200k EUR to 1500k EUR", and says it can lead rounds or coinvest. Its approach page says the method is informed by Stanford's Biodesign methodology and that its "sweet spot" is "seeding founders who are marrying in-depth understanding of the complex network of healthcare system participants with meaningful engineering innovation". Geography is pan-European with international reach including the United Kingdom, United States, Canada, Israel and Australia. The homepage states "3 funds currently under management since 2019" and "58 companies invested into by our managed funds"; the firm's July 2026 press-release boilerplate says "Since 2019, Nina Capital has invested in over 50 companies across nearly 20 countries".
Over €100M (total assets under management, February 2025, reported at the first close of the €50M Fund III) AUM64/100 Power Score™2019 FoundedBarcelona, Spain
Health TechDigital HealthDataAIHealthcare ITMedical Devices
NINA CAPITAL SGEIC, S.A. is entered on the CNMV register of venture capital management companies as number 148 on 19 July 2019, at C/ Tuset 20, 5a planta, 08006 Barcelona, with share capital of 150,000.00 euros.
2019
NINA CAPITAL FUND I, FCRE is registered with the CNMV as number 14 on 30 July 2019; a July 2021 firm press release gives Fund I a size of EUR 18 million.
2021
NINA CAPITAL FUND II, FCRE is registered with the CNMV as number 39 on 4 June 2021; on 28 July 2021 the firm announces five more investments and the launch of a second fund set to reach EUR 40 million.
2022
On 16 February 2022 the firm announces that Fund II closed oversubscribed, stating it "eclipsed its target size of EUR40 million in just four months", and names its first four Fund II investments.
2024
NINA CAPITAL FUND III, FCRE is registered with the CNMV as number 139 on 16 February 2024.
2025
In February 2025 the firm announces the first close of its EUR 50 million Fund III, reported as taking total assets under management to over EUR 100 million.